RFP ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 338 | Progressive familial intrahepatic cholestasis | 1 |
338. Progressive familial intrahepatic cholestasis
Clinical trials : 60 / Drugs : 26 - (DrugBank : 6) / Drug target genes : 2 - Drug target pathways : 2
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000017823 | 2013/07/17 | 05/06/2015 | A study to assess the safety and efficacy of rifampicin for progressive familial intrahepatic cholestasis (PFIC) and benign recurrent intrahepatic cholestasis (BRIC) | A study to assess the safety and efficacy of rifampicin for progressive familial intrahepatic cholestasis (PFIC) and benign recurrent intrahepatic cholestasis (BRIC) - A study to assess the safety and efficacy of rifampicin for progressive familial intrahepatic cholestasis (PFIC) and benign recurrent intrahepatic cholestasis (BRIC) | Progressive familial intrahepatic cholestasisBenign recurrent intrahepatic cholestasis | Rifampicin (RFP, 10 mg/kg/day) are given for 4-8 weeks. When RFP is effective against cholestasis, RFP will be tapered 2.5mg/kg per a week and withdrawn after 4 weeks. When bilirubin level does not decrease or the continuation of RFP is difficult for some side effects, RFP will be withdrawn. | Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University | NULL | Complete: follow-up complete | Not applicable | Not applicable | Male and Female | 3 | Not selected | Japan |